"Novo Nordisk's Amycretin: A Game-Changer in Weight Loss Treatment"
TL;DR
Novo Nordisk's new weight-loss drug, Amycretin, has shown promising results in an early-stage trial, with participants losing 13.1 percent of their body weight in just 12 weeks. The once-daily pill targets two hormones and has demonstrated a high retention rate and favorable safety profile. While the drug's performance has led to an 8 percent jump in Novo Nordisk shares, further trials and regulatory approval are still needed before it becomes available to patients.
- New Weight-Loss Drug Amycretin Has Patients Losing 13% of Body Weight in Just 3 Months Best Life
- Ozempic or Tesla? Markets are in no doubt which is hotter CNN
- Novo valuation surpasses Tesla on experimental obesity drug data Reuters
- Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug CNBC
- Novo Nordisk stock hits record on new weight loss drug trial Quartz
Want the full story? Read the original reporting
Read on Best Life